|
⚲
|
| Keyboard |
| Sofinnova Investments Inc
✚
|
|
|---|---|
| CRD # | 160297 |
| SEC # | 801-110134 |
| CIK # | 0001631134 |
| AUM | 5,368.5 M (2026-03-27) |
| Employees | 41 (49% Investors, 0% Brokers) |
| Phone | 650-681-8420 |
| Address | 3000 Sand Hill Road Menlo Park, CA 94025 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Natera Inc | 0.3 | ||
| United Therapeutics Corp | 0.1 | ||
| Bristol Myers Squibb Co | 0.1 | ||
| Jazz Pharmaceuticals Inc | 0.1 | ||
| Vera Therapeutics Inc | 0.1 | ||
| Astrazeneca PLC | 0.1 | ||
| UNUM Therapeutics Inc | 0.1 | ||
| Celcuity Inc | 0.1 | ||
| Ultragenyx Pharmaceutical Inc | 0.1 | ||
| Axsome Therapeutics Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Sofinnova Venture Partners XII LP | [2025-03-20] | 500.0 M | 20.5 M |
| Offered $550,000,000 · Filed 2025-08-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $49,971,939 · Duration One year or less · Commission $1,966,594 · Revenue Not Applicable | ||||
| HF | Sofinnova Bioequities Enhanced Master Fund LP | [2023-03-29] | 41.5 M | 1,194.9 M |
| Filed 2025-10-10 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Sofinnova Synergy Master Fund LP | [2022-03-30] | 4.9 M | |
| Filed 2024-10-02 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| VC | Sofinnova Venture Partners Xi LP | [2022-03-30] | 500.0 M | 308.7 M |
| Offered $500,000,000 · Filed 2023-09-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Commission $2,869,725 · Revenue Not Applicable | ||||
| HF | Sofinnova Bioequities Master Fund Ltd | [2017-03-03] | 363.7 M | 121.4 M |
| Filed 2025-05-09 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| VC | Sofinnova Venture Partners X LP | [2017-03-03] | 595.5 M | 259.3 M |
| Offered $650,000,000 · Filed 2016-08-23 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $54,500,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | Sofinnova Venture Partners IX LP | [2015-03-27] | 389.3 M | |
| Offered $500,000,000 · Filed 2014-07-10 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $500,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | 80 | [2014-03-27] | 65.3 M | 2.2 M |
| Offered $110,000,000 · Filed 2014-07-07 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $44,650,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | 194 | 2012-03-30 | 0.0 M | |
| VC | 294 | 2012-03-30 | 0.2 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 9 | 2.9 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 11 | 2.4 |
| (n) Other | 0 | 0.0 |
| Total | 20 | 5.4 |
| By Discretionary | ||
| Discretionary | 20 | 5.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 20 | 5.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 3.3 | |
| United States Persons | 2.1 | |
| Total | 20 | 5.4 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| James Healy | Executive Officer | 49 | 4 | |
| Garheng Kong | Executive Officer | 60 | 3 | |
| David Kabakoff | Executive Officer | 29 | 3 | |
| Srinivas Akkaraju | Executive Officer | 28 | 3 | |
| Randy Scott | Executive Officer | 26 | 3 | |
| Michael Powell | Executive Officer | 52 | 2 | |
| Anand Mehra | Executive Officer | 20 | 2 | |
| Maha Katabi | Executive Officer | 13 | 2 | |
| Sofinnova Investments Inc | Executive Officer | 3 | 2 | |
| Tom Callaway | Executive Officer | 2 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001631134] | |
| SC 13G | [0001631134] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Sofinnova Investments Inc | Marinus Pharmaceuticals Inc | [2024-11-14] |
| Sofinnova Investments Inc | Otonomy Inc | [2021-02-16] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300HVTF5RFS1C0D72 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Vestal Point Capital LP
✚
|
NY | 5,469.1 M |
|
Palestra Capital Management LLC
✚
|
NY | 5,441.9 M |
|
STWD Investment Management LLC
✚
|
FL | 5,434.0 M |
|
Aquatic Capital Management LLC
✚
|
IL | 5,430.4 M |
|
Stockbridge Partners LLC
✚
|
MA | 5,411.2 M |
|
Blackstone Alternative Investment Advisors LLC
✚
|
NY | 5,391.0 M |
|
Silver Rock Financial LP
✚
|
CA | 5,381.0 M |
|
Ashoka Whiteoak Capital PTE Ltd
✚
|
5,378.8 M | |
|
Mantle Ridge LP
✚
|
NY | 5,348.8 M |
|
Polus Capital Management Limited
✚
|
5,319.4 M |